Related Experiment Video

Updated: May 3, 2026

Intramuscular Transplantation of Human Pluripotent Stem Cell-derived Pancreatic Endocrine Cells in Mice
06:53

Intramuscular Transplantation of Human Pluripotent Stem Cell-derived Pancreatic Endocrine Cells in Mice

Published on: April 10, 2026

93

Targeting the pancreatic β-cell to treat diabetes

Amedeo Vetere1, Amit Choudhary2, Sean M Burns3

  • 1Chemical Biology Program, Center for the Science of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.

Nature Reviews. Drug Discovery
|February 15, 2014
PubMed

Insights

Diabetes affects millions globally, with limited new treatments. This review highlights promising strategies targeting pancreatic beta cells to improve glucose control for type 1 and type 2 diabetes.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Cell Biology

Background:

  • Diabetes mellitus represents a significant global health challenge, impacting over 500 million individuals by 2030.
  • Current therapeutic options for diabetes have not kept pace with the escalating disease burden.
  • The pancreatic beta cell is recognized as a critical factor in the development of both type 1 and type 2 diabetes.

Purpose of the Study:

  • To provide an overview of recent advancements in diabetes treatment strategies.
  • To focus on novel approaches targeting the pancreatic beta cell.

Main Methods:

  • Literature review of recent developments in beta-cell-targeted diabetes therapies.
  • Analysis of promising strategies for preserving, expanding, and improving beta-cell function.

Main Results:

  • Identification of key therapeutic targets within the pancreatic beta cell.
  • Overview of emerging strategies for enhancing beta-cell function and survival.

Conclusions:

  • Targeting the pancreatic beta cell offers a promising avenue for improved diabetes management.
  • Further research into beta-cell-centric therapies is crucial for addressing the growing diabetes epidemic.

More Related Videos

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination12:33

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination

Published on: June 25, 2014

64.9K
Isolated Pancreatic Islet Treatment and Apoptosis Measurement09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

965

Related Concept Videos

Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
2.1K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
2.8K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
75
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.5K